S. Biotek

S. Biotek is a South Korean clinical-stage biotechnology company specializing in the development of advanced cell therapies for neurological, musculoskeletal, and dermatological conditions. The company utilizes its proprietary TED (Tissue Engineering & Development) and FECS (Functionally Enhanced Cell Spheroid) platforms to differentiate embryonic stem cells (hESCs) and adult stem cells into functional therapeutic agents. Its lead clinical programs include TED-N for spinal cord injury and TED-P for Parkinson's disease, both of which are in Phase 1/2a trials. S. Biotek already has a commercial presence with Cureskin, an autologous fibroblast therapy approved in South Korea for the treatment of acne scars and wrinkles. The company operates its own GMP-certified manufacturing facility and is listed on the KOSDAQ exchange.